Introduction

ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties determine the pharmacokinetic profile and clinical viability of peptide therapeutics. Peptides face unique ADMET challenges compared to small molecules due to their size, polarity, and susceptibility to enzymatic degradation. This article provides a comprehensive analysis of each ADMET parameter for peptide drugs.

Absorption

Routes of Administration

1. Intravenous (IV):

• Bioavailability: 100%
• Onset: Immediate
• Applications: Acute conditions, hospital setting
• Limitations: Requires healthcare professional

2. Subcutaneous (SC):

• Bioavailability: 60–100%
• Onset: 15–60 minutes
• Applications: Chronic conditions, self-administration
• Limitations: Injection site reactions

3. Intramuscular (IM):

• Bioavailability: 75–100%
• Onset: 10–30 minutes
• Applications: Vaccines, depot formulations
• Limitations: Pain, muscle damage

4. Oral:

• Bioavailability: 0.1–5% (typical)
• Onset: 30–90 minutes
• Applications: Convenience, chronic therapy
• Limitations: Low bioavailability, variability

5. Nasal:

• Bioavailability: 1–10%
• Onset: 5–15 minutes
• Applications: Local action, CNS delivery
• Limitations: Mucociliary clearance

6. Pulmonary:

• Bioavailability: 5–20%
• Onset: 1–5 minutes
• Applications: Respiratory diseases, systemic delivery
• Limitations: Device-dependent, lung irritation

Absorption Barriers

1. Epithelial barrier:

• Tight junctions between enterocytes
• Mucus layer (100–300 μm thick)
• Glycocalyx (0.1–0.5 μm)

2. Enzymatic degradation:

• Luminal proteases (trypsin, chymotrypsin)
• Brush border peptidases
• Intracellular peptidases

3. Physical properties:

• Molecular weight: >500 Da limits passive diffusion
• Hydrophilicity: LogP < 0 limits membrane partitioning
• Charge: Zwitterions less permeable than neutral species

Absorption Enhancement Strategies

1. Chemical modifications:

• N-methylation: Reduces HBD, enhances permeability
• D-amino acids: Resists proteolysis
• Cyclization: Reduces conformational entropy
• Lipidation: Enhances membrane interaction

2. Formulation approaches:

• Permeation enhancers (EDTA, bile salts)
• Mucoadhesive systems
• Nanoparticles (liposomes, polymeric)
• Microemulsions

3. Enzyme inhibitors:

• Protease inhibitors (aprotinin, bestatin)
• Combined with peptide formulation

Distribution

Volume of Distribution (Vd)

Peptide Type	Vd (L/kg)	Distribution Pattern
Small peptides (< 1 kDa)	0.2–0.5	Extracellular fluid
Medium peptides (1–5 kDa)	0.1–0.3	Plasma, extracellular
Large peptides (> 5 kDa)	0.05–0.15	Primarily plasma
PEGylated peptides	0.05–0.2	Confined to plasma
Albumin-bound peptides	0.05–0.1	Plasma, extracellular

Protein Binding

1. Albumin binding:

• Most peptides show 50–99% protein binding
• Binding is concentration-dependent
• Affects free fraction and distribution

2. Lipoprotein binding:

• Some peptides bind to LDL/HDL
• Affects tissue distribution

3. α₁-Acid glycoprotein:

• Basic peptides may bind
• Affects distribution to tissues

Tissue Distribution

1. Liver:

• Primary site of peptide uptake
• Hepatocyte摄取 via receptor-mediated endocytosis
• First-pass metabolism

2. Kidney:

• Glomerular filtration of peptides < 60 kDa
• Tubular reabsorption
• Degradation by brush border enzymes

3. Brain:

• Blood-brain barrier (BBB) limits entry
• Some peptides cross via:
  • Receptor-mediated transcytosis
  • Adsorptive-mediated transcytosis
  • Intranasal delivery

4. Tumor tissue:

• Enhanced permeability and retention (EPR) effect
• Passive accumulation in tumors
• Active targeting via peptide ligands

Blood-Brain Barrier (BBB) Penetration

Requirements for BBB crossing:

• MW < 400–500 Da
• LogP 1–3
• PSA < 90 Ų
• Low hydrogen bonding capacity

Strategies for BBB penetration:

1. Cell-penetrating peptide conjugation
2. Transferrin receptor targeting
3. Intranasal delivery
4. Focused ultrasound

Metabolism

Proteolytic Degradation

1. Endopeptidases:

• Neprilysin (NEP): Cleaves at hydrophobic residues
• Angiotensin-converting enzyme (ACE): Cleaves dipeptides from C-terminus
• Dipeptidyl peptidase IV (DPP-IV): Cleaves X-Pro sequences

2. Exopeptidases:

• Aminopeptidases: N-terminal cleavage
• Carboxypeptidases: C-terminal cleavage

3. Cleavage site specificity:

Protease	Cleavage Site	Specificity
Trypsin	Lys, Arg (C-terminal)	Basic residues
Chymotrypsin	Phe, Trp, Tyr (C-terminal)	Aromatic residues
Elastase	Ala, Gly, Val (C-terminal)	Small residues
DPP-IV	X-Pro (N-terminal)	Proline at P1

Hepatic Metabolism

1. Cytochrome P450 (CYP):

• Limited role in peptide metabolism
• Some peptide modifications (e.g., N-methylation) may affect CYP

2. Phase II metabolism:

• Glucuronidation: Limited for peptides
• Sulfation: Minor pathway
• Acetylation: Some peptides

Metabolic Stability Strategies

1. Structural modifications:

• D-amino acid substitution
• N-methylation
• Cyclization
• β-amino acid incorporation

2. Metabolic soft spots:

• Identify by in vitro incubation with liver microsomes
• Target for modification

3. Formulation approaches:

• PEGylation: Shield from proteases
• Albumin binding: Reduce renal clearance

Excretion

Renal Excretion

1. Glomerular filtration:

• Molecular weight cutoff: ~60 kDa
• Filtered peptides are reabsorbed or degraded
• Some reabsorbed via megalin/cubilin

2. Tubular secretion:

• Organic anion transporters (OAT)
• Organic cation transporters (OCT)

3. Urinary excretion:

• Intact peptides: Minimal
• Metabolites: Major form

Hepatic Excretion

1. Biliary excretion:

• Larger peptides (> 500 Da)
• Active transport via MRP2
• Enterohepatic recirculation possible

2. Fecal excretion:

• Degraded peptides
• Unabsorbed peptides

Half-life Determinants

Parameter	Effect on Half-life	Optimization Strategy
Renal clearance	↓ Half-life	PEGylation, albumin binding
Proteolysis	↓ Half-life	D-amino acids, cyclization
Distribution	Variable	Optimize lipophilicity
Protein binding	↑ Half-life	Fatty acid acylation

Toxicity

Acute Toxicity

1. Injection site reactions:

• Pain, redness, swelling
• Concentration-dependent
• Formulation optimization

2. Anaphylaxis:

• Rare but serious
• Requires epinephrine availability
• Pre-medication in high-risk patients

3. Hypotension:

• Histamine release
• Peptide-specific (e.g., protamine)

Chronic Toxicity

1. Immunogenicity:

• Anti-drug antibodies (ADA)
• May reduce efficacy or cause adverse effects
• Monitoring required

2. Organ toxicity:

• Hepatotoxicity: Rare for peptides
• Nephrotoxicity: Possible with cationic peptides
• Cardiotoxicity: Very rare

3. Tumorigenicity:

• Unlikely for peptides
• Long-term monitoring for growth factors

Genotoxicity and Mutagenicity

Peptides are generally non-genotoxic:

• No DNA intercalation
• No alkylating activity
• Metabolites are amino acids

Reproductive Toxicity

1. Teratogenicity:

• Low risk for most peptides
• Some hormones may affect development

2. Fertility:

• GnRH analogs: Intentional fertility suppression
• Other peptides: Generally safe

Safety Assessment

1. In vitro assays:

• Cytotoxicity (MTT, LDH)
• Ames test (generally negative)
• hERG channel inhibition

2. In vivo studies:

• Acute toxicity (single dose)
• Repeat-dose toxicity (28-day, 90-day)
• Reproductive toxicity
• Carcinogenicity (2-year)

Clinical ADMET Considerations

Patient Factors

1. Renal impairment:

• Reduce dose for renally cleared peptides
• Monitor renal function
• Adjust based on GFR

2. Hepatic impairment:

• Most peptides not hepatically metabolized
• Monitor for accumulation
• Reduce dose if needed

3. Age:

• Pediatric: Different pharmacokinetics
• Elderly: May have reduced clearance

Drug Interactions

1. Protease inhibitors:

• ACE inhibitors: May increase peptide levels
• DPP-IV inhibitors: Affect incretin peptides

2. P-glycoprotein modulators:

• Limited effect on peptides
• Some peptides are P-gp substrates

3. CYP inhibitors:

• Generally not relevant for peptides
• Some modified peptides may be affected

Analytical Methods for ADMET

In Vitro Assays

1. Stability assays:

• Plasma stability: Incubation in human plasma
• Liver microsome stability: Metabolic stability
• Caco-2 permeability: Intestinal permeation

2. Binding assays:

• Plasma protein binding: Equilibrium dialysis
• Tissue binding: Homogenate binding

In Vivo Studies

1. Pharmacokinetic studies:

• Species: Mouse, rat, non-human primate
• Sampling: Serial blood collection
• Analysis: LC-MS/MS, immunoassay

2. Mass balance studies:

• Radiolabeled peptides
• Excretion routes: Urine, feces, bile

Summary

Peptide ADMET properties are governed by molecular size, charge, hydrophobicity, and metabolic susceptibility. Key challenges include rapid proteolysis, poor membrane permeability, and renal clearance. Strategies to optimize ADMET include structural modifications (N-methylation, D-amino acids, cyclization), formulation approaches (PEGylation, nanoparticles), and targeting strategies (albumin binding, receptor-mediated transport). Understanding these parameters is essential for rational design of peptide therapeutics with clinical viability.

Deep dive: Explore Peptide Pharmacokinetics for detailed PK modeling, or read about Peptide Toxicology for comprehensive safety assessment.

Test yourself: Take the Peptide ADMET Quiz or study with ADMET Flashcards.